PulseCath BV’s Post

🚀 Another successful complex high-risk PCI with the support of iVAC 2L, pulsatile percutaneous ventricular assist device, was performed by Dr. Anton Farkas, Director Medical Affairs Cardiology Center Agel, Košice and cathlab team. 👨⚕️ Procedure: male, 79 years old, NYHA class IV, EF 10%, SYNTAX Score 41, elective, Peripheral Artery Disease, Surgery refusal, 3-vessel disease. Vessels to be treated LM, LCx, RCA. Femoral artery was heavily calcified and Shockwave IVL System was used. One stent deployed in RCA. PCI support time with iVAC 2L was 68 minutes, flow 1.8 L/min. ACT target around 309. Femoral artery closed with double Perclose ProGlide closure device. ⚡️Congratulations and thank you to Dr. Anton Farkas and cathlabteam. We are grateful for the long-standing and trustful cooperation in the field of short-term Mechanical Circulatory Support, also big thanks to our partner Globalmed Michal Rzounek, Jozef Kubela and team. Helena Podrzaj   #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation 

 🔎About today in London at the London Core Review Meeting. 👉 Want to learn more about iVAC 2L, pulsatile percutaneous ventricular assist device, for protected high-risk PCI? Our experts from DOT Medical are at your disposal at the booth or request a demo via: https://lnkd.in/e-5qmgwQ Ian Rankin Krista Chappell-Jones Helena Podrzaj #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI https://lnkd.in/eCnYWe4B

⚡️We are pleased to share a new publication: Hemodynamical Evaluation of a New Surgically Implanted Pulsatile Right Ventricular Assist Device Driven by a Conventional Intra-Aortic Balloon Pump Console by Dr. Sara Knigge, Dr. Günes Dogan et all. ASAIO Journal 2024. 🔸 New Pulsatile Ventricular Assist Platform, pVAP 🔸 This platform builds on the proven IVAC 2L technology 🔸 Driven by standard IABP console 🔸 Compatible with all available standard cannulas  The main findings indicate that the pVAP is feasible and effective. ✅ the output flow of the pVAP is directly influenced by the pressure in the output chamber; ✅ the pVAP produces an output of 2.7 L/min; ✅ the pVAP has a minor, but observable, hemodynamic effect in healthy individuals; ✅ in cases of acute RVF, activating the pVAP significantly improves hemodynamics in both the pulmonary and aortic circulations.   🚩Conclusion: This initial experience with the pVAP prototype demonstrates its feasibility as a VAD and effectiveness in restoring hemodynamics in porcine models of acute RVF. 👉 Full publication: https://lnkd.in/ecgtY4Qk   Special thanks to Prof. Dr. J. D. Schmitto, MD, PhD, MBA, FRCS(Glasg) FACS, Director of the Mechanical Circulatory Support Medizinische Hochschule Hannover and team. Oren Malchin   Would you like to know more? Please leave a message via our website: https://lnkd.in/eRSFAWJV   #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

🌟 The CEO Views is proud to recognize PulseCath, a medical device company as one of the ‘Top 50 Most Innovative Companies to Watch 2024’. The award felicitates PulseCath for its innovation, determination and relentless pursuit towards becoming a leader in mechanical circulatory support while ensuring that life-saving solutions remain accessible to all. We are very proud with this recognization and the award. Please check also the interview with our CEO, Oren Malchin via this link.  https://lnkd.in/eUiFuFF7 #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

🚀A new milestone in Oman. We are thrilled to announce the first protected High-Risk PCI with the successful support of iVAC 2L performed by Drs. Hatim Al-Lawati and Dr. Khalid Al-Saidi Royal Hospital/National Heart Center in Muscat, Oman. 👨⚕️ Procedure: male, 62 years old, EF 20%, NYHA IV, elective procedure with a long LAD and CX calcification. First LAD was rotablated and checked with IVUS, 2 stents have been positioned after the rotablation, and CX was also treated with two stents. Patient remained very stabile during the critical part of the intervention (rotablation ) and the procedure could be performed without any problems. Overall PCI support with iVAC 2L was 73 minutes, average support of 1.2 liters per minute. ACT target around 360. Femoral artery closed with double Perclose ProGlide closure device. 🌟Congratulations and a huge thanks to Drs. Hatim Al-Lawati and Dr. Khalid Al-Saidi, cathlab team and our local partner GLE Medical, Omar Khatib, Ayman El Massri and team. uwe p. kasten Maja Krizaj   #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

📢  In Poland a new center started with a successful iVAC 2L case, pVAD – Percutaneous Ventricular Assist Device. The protected High-Risk PCI was performed by Dr. Piotr Wańczura, Dr. Grzegorz Sobieszek, Dr. Wojciech Stecko, Dr. Wiśniowski in hospital MSWiA Al. Krakowska in Rzeszow. 🏥 Female, 65 years old, EF 50%, indication: urgent ACS, DMII, Hypertension, Kidney Failure, Dyslipidemia, Previous PCI. Vessel to treated LAD. In total 4 stents deployed, IVUS guided procedure. PCI support time with iVAC 2L was 100 minutes, max. iVAC 2L flow 2.0 L/min. ACT target around 400. The femoral artery was surgical closed. 🌟Congratulations to Dr. Piotr Wańczura, Dr. Grzegorz Sobieszek, Dr. Wojciech Stecko, Dr. Wiśniowski and the cathlab team. Also big thanks to our partner MedAccess, Wojciech Plisiecki, Piotr Zdziarski, Łukasz Andrzejewski, MBA and Dariusz Mucha. Maja Krizaj #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

💡 In Germany we are with our partner CoRRect Medical GmbH present at the 90th Annual DGK Meeting - German Cardiology Congress in Mannheim. The conference will take place at the Congress Center Rosengarten from 3-6 April. Want to know more about iVAC 2L, pulsatile percutaneous ventricular assist device, for protected high-risk PCI? Our experts are at your disposal. uwe p. kasten Michael Braun or book a demo? Please leave a message or visit our website. www.pulsecath.com #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

💡In Slovakia another successful iVAC 2L protected high-risk PCI was performed by Dr. Anton Farkas: "iVAC 2L for us represents a very beneficial clinical tool in the management of severe coronary findings, especially in patients with severe heart failure and acute coronary syndrome." 🌟Thanks team Kardiocenter AGEL and our partner Michal Rzounek Jozef Kubela Helena Podrzaj #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

💡 Together with our partner EUKON S.r.l.e. we are exhibiting JIM-GISE Interventional Cardiology Congress on 20-23 March 2024 in Rome.    🫀 Today there was a special Golden hour session pVAD in MitraClips with dr. Davide D’Andrea from AORN Cardarelli, Naples. 👉 Please join us 22 March,1 pm, at the session: “Optimizing PCI outcomes in high-risk Patients” by Prof. Nicolas Van Mieghem, Erasmus Medical Center, Rotterdam, The Netherlands. Want to learn more about iVAC 2L, pulsatile percutaneous ventricular assist device, for protected high-risk PCI? Our experts are at your disposal.  See you in Rome? Gennaro Broya de Lucia Valentina Casanova Pasquale Di Canio Claudia Mugnoz Maja Krizaj Oren Malchin #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

📢 In Italy a new center started with a successful iVAC 2L procedure, pVAD – Percutaneous Ventricular Assist Device.  🌟Congratulations to the team Ospedale “Morgagni - Pierantoni” in Forlì, Italy and team EUKON Massimiliano D'Agostino Pasquale Di Canio Claudia Mugnoz Gennaro Broya de Lucia Oren Malchin Davide Fiscella Maja Krizaj #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI https://lnkd.in/eZMDHjYr